Empirical TB treatment comes up short again
Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low
Large-scale household TB screening shows feasibility in PopART trial
Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016
Early antiretroviral therapy reduces the risk of infection-related cancers
HIV in the brain: new tools and treatment to keep your mind beautiful
Removing clinic barriers to rapid initiation of ART in Uganda enables 70% to start on the same day
Dolutegravir safe and highly effective in older children
Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed
